12:00 AM
 | 
Jun 17, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Iluvien regulatory update

The U.K.'s NICE issued draft guidance recommending the use of Iluvien fluocinolone acetonide intravitreal implant from Alimera for a subset of patients with chronic diabetic macular edema (DME). The committee recommends use of Iluvien to treat DME considered insufficiently responsive to available therapies but only in patients who have had their natural lens replaced with an intraocular lens....

Read the full 269 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >